Fluoroquinolone Resistance Mutations in the parC , parE , and gyrA Genes of Clinical Isolates of Viridans Group Streptococci

Author:

González Irene1,Georgiou Marios12,Alcaide Fernando3,Balas Delia1,Liñares Josefina3,de la Campa Adela G.1

Affiliation:

1. Unidad de Genética Bacteriana (Consejo Superior de Investigaciones Cientı́ficas), Centro Nacional de Biologı́a Fundamental, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid,1 and

2. University of Greenwich, London, United Kingdom2

3. Servicio de Microbiologı́a, Hospital Princeps d’Espanya, Ciutat Sanitària i Universitaria de Belltvitge, 08907 L’Hospitalet de Llobregat, Barcelona,3 Spain, and

Abstract

ABSTRACT The nucleotide sequences of the quinolone resistance-determining regions (QRDRs) of the parC and gyrA genes from seven ciprofloxacin-resistant (Cp r ) isolates of viridans group streptococci (two high-level Cp r Streptococcus oralis and five low-level Cp r Streptococcus mitis isolates) were determined and compared with those obtained from susceptible isolates. The nucleotide sequences of the QRDRs of the parE and gyrB genes from the five low-level Cp r S. mitis isolates and from the NCTC 12261 type strain were also analyzed. Four of these low-level Cp r isolates had changes affecting the subunits of DNA topoisomerase IV: three in Ser-79 (to Phe or Ile) of ParC and one in ParE at a position not previously described to be involved in quinolone resistance (Pro-424). One isolate did not show any mutation. The two high-level Cp r S. oralis isolates showed mutations affecting equivalent residue positions of ParC and GyrA, namely, Ser-79 to Phe and Ser-81 to Phe or Tyr, respectively. The parC mutations were able to transform Streptococcus pneumoniae to ciprofloxacin resistance, while the gyrA mutations transformed S. pneumoniae only when mutations in parC were present. These results suggest that DNA topoisomerase IV is a primary target of ciprofloxacin in viridans group streptococci, DNA gyrase being a secondary target.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3